Results are presented as mean ± SD for the 39 patients who had cholesterol and HDL tests completed at visit 3 (after placebo washout) and visit 9 (after six months on randomized treatment). Among those randomly assigned to HCTZ, 21 (16 men and five women) completed the study; 18 patients (10 men, eight women) completed the study on indapamide. An intention-to-treat analysis was also conducted.
There were no cases of type III hyperlipidemia with apoE phenotype E2E2; the distribution of phenotypes in the patients randomly assigned to indapamide was not significantly different – E3E2 in three cases, E3E3 in 12 cases, E4E3 in one case and two missing. Among those randomly assigned to HCTZ there were four with E3E2, seven with E3E3, five with E4E3 and one with E4E4; four were missing (P=0.40). buy ortho tri-cyclen online
Baseline variables for the two treatment groups are presented in Table 1. Supine and standing SBP were significantly higher at baseline in the patients randomly assigned to inda-pamide.
TABLE 1 Baseline variables for the two treatment groups at visit three (after placebo run-in)
|Supine systolic blood pressure (mmHg)||155.2±18.3||144.2±8.5||0.03*|
|Supine diastolic blood pressure (mmHg)||98.0±3.8||96.6±5.1||0.33|
|Supine heart rate (beats/minute)||79.5±12.5||77.6±9.6||0.61|
|Standing systolic blood pressure (mmHg)||154.8±18.4||143.9±10.3||0.04*|
|Standing diastolic blood pressure (mmHg)||91.4±6.1||94.6±5.1||0.49|
|Standing heart rate (beats/minute)||82.1±12.1||80.9±8.7||0.75|
|Total cholesterol (mmol/L)||4.86±0.70||5.09±0.59||0.20|
Results are given as mean±SD. Analysis was by one-way ANOVA. *Significant. apoAl Apolipoprotein AI; apoB Apolipoprotein B; HCTZ Hydrochlorothiazide; HDL High density lipoprotein cholesterol; LDL Low density lipoprotein cholesterol
Table 2 presents results for electrolytes, blood glucose and uric acid at entry visit and after six months. Both indapamide and HCTZ significantly reduced serum potassium (P<0.001) and increased uric acid (P=0.05) from baseline, but there were no significant differences between the treatments.
TABLE 2 Electrolytes, creatinine blood glucose and uric acid at baseline (visit one) and after six months (visit nine)